Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment

Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2023-07, Vol.13 (7), p.1114
Main Authors: Waldstein, Sasha, Spengler, Marianne, Pinchuk, Iryna V, Yee, Nelson S
Format: Article
Language:English
Subjects:
Antibiotics
Biofilms
Biomarkers
Biopsy
Blood
Cancer
Cancer therapies
Carcinogenesis
Carcinogens
Care and treatment
Clinical outcomes
Colorectal cancer
Colorectal carcinoma
Kinases
Medical prognosis
Microbiomes
Microbiota
Morphology
Mutation
Patient outcomes
Precision medicine
Prognosis
Rectum
Review
Trends
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for known mutational differences, tumor side of origin has emerged as an independent prognostic factor, and one that impacts response to therapy. Left- and right-sided colon cancers differ in a number of key ways, including histology, mutational profile, carcinogenesis pathways, and microbiomes. Moreover, the frequency of certain molecular features gradually changes from the ascending colon to rectum. These, as well as features yet to be identified, are likely responsible for the ongoing role of tumor sidedness and colorectal subsites in treatment response and prognosis. Along with tumor molecular profiling, blood-based biopsy enables the identification of targetable mutations and predictive biomarkers of treatment response. With the application of known tumor characteristics including sidedness and subsites as well as the utilization of blood-based biopsy, along with the development of biomarkers and targeted therapies, the field of colorectal cancer continues to evolve towards the personalized management of a heterogeneous cancer.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm13071114